Interestingly, previous studies have revealed that selinexor pre-treatment increase T cell activation against B cell malignancies (28) and breast cancer cells (27) however the contribution of HLA-E/NKG2A interactions in these settings were not investigated. This evidence concerns the gene KLRC1 and breast carcinoma.